| P50 | author | Lars Christian Gormsen | Q57005260 |
| | Kresten Krarup Keller | Q64521039 |
| | Berit Dalsgaard Nielsen | Q90678628 |
| P2093 | author name string | Ellen-Margrethe Hauge | |
| | Ib Tønder Hansen | |
| | Philip Therkildsen | |
| P2860 | cites work | The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease | Q45300713 |
| | [18F] FDG-PET/CT as a new and sensitive imaging method for the diagnosis of large vessel vasculitis | Q46361872 |
| | Issues in trial design for ANCA-associated and large-vessel vasculitis | Q48937679 |
| | Positron Emission Tomography/Computerized Tomography in Newly Diagnosed Patients with Giant Cell Arteritis Who Are Taking Glucocorticoids | Q50062207 |
| | BSR and BHPR guidelines for the management of giant cell arteritis. | Q51706743 |
| | Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. | Q51723974 |
| | Assessment of aortitis by semiquantitative analysis of 180-min 18F-FDG PET/CT acquisition images. | Q53058998 |
| | Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. | Q53073312 |
| | Towards an optimal semiquantitative approach in giant cell arteritis: an (18)F-FDG PET/CT case-control study. | Q53096424 |
| | The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. | Q53142320 |
| | Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. | Q53179293 |
| | False-Negative Temporal Artery Biopsy | Q68144443 |
| | 18F-FDG PET as a diagnostic procedure in large vessel vasculitis—a controlled, blinded re-examination of routine PET scans | Q82037506 |
| | Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis | Q26852724 |
| | Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. | Q31150307 |
| | Disease pattern in cranial and large-vessel giant cell arteritis | Q33534693 |
| | Diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis | Q33895383 |
| | Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients | Q33993390 |
| | FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. | Q35043725 |
| | Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study | Q35554263 |
| | Large-vessel giant cell arteritis: a cohort study. | Q35588160 |
| | Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization | Q36256143 |
| | Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). | Q36305268 |
| | Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern. | Q37077856 |
| | EULAR recommendations for the management of large vessel vasculitis. | Q37138796 |
| | Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis: A real-life prospective study. | Q37605575 |
| | Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review | Q37915349 |
| | The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. | Q38786203 |
| | Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? | Q38853148 |
| | Design of the tocilizumab in giant cell arteritis trial | Q40195385 |
| | Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. | Q40322778 |
| | A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis | Q40353912 |
| | Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. | Q40562002 |
| | Large-vessel vasculitis: interobserver agreement and diagnostic accuracy of 18F-FDG-PET/CT. | Q43142797 |
| | Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio | Q43936771 |
| P433 | issue | 7 | |
| P921 | main subject | giant cell arteritis | Q707816 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 1119-1128 | |
| P577 | publication date | 2018-04-18 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. | |
| P478 | volume | 45 | |